Last month, biopharmas let go or projected they would let go of less than 500 people combined, based on BioSpace estimates, down almost 1,000 from January 2025. Still, competition for open jobs ...
The peptide synthesis market is expanding due to growing demand for peptide-based therapeutics, driven by superior target specificity and lower toxicity. Innovations like microwave-assisted SPPS ...
In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.
Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated ...
In an era when Washington seems incapable of finding common ground on virtually any issue, it’s notable to encounter a policy area where stakeholders across the political spectrum agree. Gene ...
Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...
A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results